<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190427043384N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-03-17</date_registration>
      <primary_sponsor>Kharazmi University</primary_sponsor>
      <public_title>Effects of pain neuroscience training combined with neuromuscular exercises on chronic low back pain</public_title>
      <acronym></acronym>
      <scientific_title>Effects of pain neuroscience training combined with neuromuscular exercises on pain, functional disability and psychological factors related to chronic low back pain: A study protocol for a randomized controlled trial.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-03-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69146</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: a researcher will generate the allocation sequence with a block size of two using an online random number generator (Random.org). Patients will be randomly assigned into one of two treatment groups in the ratio of 1:1 as follows: PNE plus NMS group (n = 30) or control group (n = 30). Randomization will be drawing a number from 1 to 60, prepared in advance and placed in sealed opaque envelopes in a box. Participants will be told which intervention they were randomized to at the end of the study, after eight weeks, Blinding description: Assessor and biostatistician will be blinded to group allocation. The investigators responsible for data analysis will use a coded dataset to ensure blinding. Patients will not be blinded to exercise study but will not know which treatment group they will be assigned to.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Chronic low back pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: A neuroscience and pain training protocol along with a neuromuscular exercise protocol will be performed three times a week for eight weeks. The neuroscience training protocol includes the following: - Basic explanation of the structure of the brain and nerves, peripheral nervous system and central nervous system. Thresholds of action - Explaining the process of restraining and promoting the spine - Explaining the types of sensations and the transfer process - Explaining the basic concept of neuroplasticity.                                                                           The neuromuscular training protocol includes the following: - Modified crawl-up exercise - Bird dog exercise - Side bridge exercise - Single stretch exercise Leg - shoulder bridge exercise - Tai Chi warrior exercise. Intervention 2: Control group: they will perform a protocol of neuromuscular exercises three times a week for eight weeks and will not participate in any other treatment plan. The neuromuscular training protocol includes the following: - Modified crawl-up exercise - Bird dog exercise - Side bridge exercise - Single stretch exercise Leg - shoulder bridge exercise - Tai Chi warrior exercise.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ehsan Alvani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Biomechanics and Corrective Exercise Laboratory, Faculty of Physical Education and Sport sciences, Kharazmi University, Mirdamad Blvd., Hesari St</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1435916471</zip>
        <telephone>+98 910 844 7211</telephone>
        <email>Ehsanalvani90@gmail.com</email>
        <affiliation>Kharazmi University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ehsan Alvani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Biomechanics and Corrective Exercise Laboratory, Faculty of Physical Education and Sport sciences, Kharazmi University, Mirdamad Blvd., Hesari St</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1435916471</zip>
        <telephone>+98 910 844 7211</telephone>
        <email>Ehsanalvani90@gmail.com</email>
        <affiliation>Kharazmi University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>-Persian-native speaker (Male and Female )
- Primary complaints of low back pain (more than three months, usually between the lower ribs and the creased part of the buttocks without nonspecific pathoanatomical cause) diagnosed by an experienced physiotherapist and completion of the consent form.</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>-previous spinal surgery and neurological signs
specific spinal pathology (tumor, infection, fracture, inflammatory disease)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M54.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Low back pain M54.5</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: A neuroscience and pain training protocol along with a neuromuscular exercise protocol will be performed three times a week for eight weeks. The neuroscience training protocol includes the following: - Basic explanation of the structure of the brain and nerves, peripheral nervous system and central nervous system. Thresholds of action - Explaining the process of restraining and promoting the spine - Explaining the types of sensations and the transfer process - Explaining the basic concept of neuroplasticity.                                                                           The neuromuscular training protocol includes the following: - Modified crawl-up exercise - Bird dog exercise - Side bridge exercise - Single stretch exercise Leg - shoulder bridge exercise - Tai Chi warrior exercise</i_keyword>
      <i_keyword>Control group: they will perform a protocol of neuromuscular exercises three times a week for eight weeks and will not participate in any other treatment plan. The neuromuscular training protocol includes the following: - Modified crawl-up exercise - Bird dog exercise - Side bridge exercise - Single stretch exercise Leg - shoulder bridge exercise - Tai Chi warrior exercise</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain Intensity. Timepoint: Data will be assessed at the three measurement time points from the participants:•	Before intervention;•	After 8 weeks of intervention•	At 6-month follow-up. Method of measurement: In this study, pain will be measured using Visual Analogue Scale (VAS) scale. The VAS, a widely used psychometric response scale tool, measures participants’ pain severity. Participants will be asked to indicate the severity of their pain along the VAS, which is a horizontal line with 10 points along it. The beginning shows no pain (marked with a zero and an image of a smiling face), and its endpoint (marked with a 10 and a face in pain and discomfort) represents very severe pain. Its reliability and validity have been excellent, and its internal consistency has been well demonstrated.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Disability. Timepoint: Data will be assessed at the three measurement time points from the participants:•	Before intervention;•	After 8 weeks of intervention•	At 6-month follow-up. Method of measurement: In the present study, The Persian version of the Oswestry questionnaire will be used to assess the degree of disability in participants with Chronic low back pain (CLBP) . This questionnaire includes 10 six-option items. These 10 items examine the performance of the individuals in their daily activities. Each item ranks the degree of disability in performance from zero (desired function with no feeling of pain) up to five (disability in performing the activity due to severe pain). The Oswestry disability index is equal to sum of the scores of these 10 items multiplied by 2, the value of which ranges from 0 to 100. A zero score indicates the person can perform daily activities with no pain. A 0-20 score indicates mild or minimal disability, 21-40 indicates moderate disability, 41-60 indicates severe disability, and 61-80 indicates crippling disability. Scores 81 and higher indicate the person is bed-bound or exaggerating symptoms. The validity of Oswestry questionnaire has been confirmed based on Cronbach alpha of 75%, and its reliability has been reported with a correlation coefficient of 0.92 using the test-retest method. The least clinically significant difference (MCD) in people with CLBP is 0.28.</sec_outcome>
      <sec_outcome>Fear-avoidance beliefs. Timepoint: Data will be assessed at the three measurement time points from the participants:•	Before intervention;•	After 8 weeks of intervention•	At 6-month follow-up. Method of measurement: The Persian version of the Fear-Avoidance Beliefs Questionnaire (FABQ) will be used to assess the patients' fear-avoidance beliefs during physical activity and work. It includes 16 items related to physical activity (FABQ-PA) and work (FABQ-W) affecting the patient’s LBP. As for FABQ-W, those with a score &gt;34 or higher (out of a possible 42 points) have shown to be less likely to return to work by four weeks, whereas, in FABQ-PA, those with a score of 15 (out of a possible 24 points) have revealed Fear-Avoidance beliefs related to physical activities. The Persian version of the FABQ has been reported to be a valid and reliable (ICC= 0.80) measure of Fear-Avoidance beliefs in patients with CLBP. The least clinically significant difference (MCD) in people with CLBP is 5.95.</sec_outcome>
      <sec_outcome>Self-efficacy. Timepoint: Data will be assessed at the three measurement time points from the participants:•	Before intervention;•	After 8 weeks of intervention•	At 6-month follow-up. Method of measurement: The Persian version of the Pain Self-Efficacy Questionnaire (PSEQ) will be used to assess self-efficacy. The questionnaire has been found to be a valid and reliable (ICC= 0.92) measure of pain self-efficacy beliefs). The PSEQ is a 10-item questionnaire ranging from 0 to 60 to assess patients’ confidence about their ability to perform a range of activities despite pain. For example: “I can do most of the household chores (e.g., tidying up, washing dishes), despite the pain” and “I can gradually increase my activity level, despite the pain. Lower scores for the PSEQ indicate lower levels of confidence. The least clinically significant difference (MCD) in people with CLBP is 5.5.</sec_outcome>
      <sec_outcome>Fear of movement. Timepoint: Data will be assessed at the three measurement time points from the participants:•	Before intervention;•	After 8 weeks of intervention•	At 6-month follow-up. Method of measurement: The Tampa Scale of Kinesiophobia (TSK) measures “fear of movement” or “kinesiophobia” in the patient. The total score on this scale is between, 17 to 68. For example, a score of 68 showed severe fear of movement, 37 indicates there is fear of movement and where 17 means no fear. It is translated and validated into Persian and has been reported (ICC test-retest = 0.86) (Cronbach’s Alpha was 0.796 in 17 items). The least clinically significant difference (MCD) in people with CLBP is 0.18).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kharazmi University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-11-21</approval_date>
        <contact_name>Sport Sciences Research Institute</contact_name>
        <contact_address>No. 3,5th  Alley,Miremad Street, Motahhari Street Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
